Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy

被引:57
|
作者
Munir, WM
Pulido, JS
Sharma, MC
Buerk, BM
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Univ Illinois, Chicago Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL USA
来源
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE | 2005年 / 40卷 / 05期
关键词
intravitreal steroids; pars plana vitrectomy; proliferative diabetic retinopathy; proliferative vitreoretinopathy; triamcinolone acetonide;
D O I
10.1016/S0008-4182(05)80052-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background: We present a retrospective evaluation of the clinical outcome and complications associated with intravitreal injection of unaltered triamcinolone acetonide in conjunction with pars plana vitrectomy and silicone oil injection for the treatment of complicated proliferative diabetic retinopathy with tractional retinal detachment and severe proliferative vitreoretinopathy. Methods: Thirteen eyes of 12 consecutive patients were identified from a computerized patient database. All eyes were operated on by the same surgeon and received 4 mg of unaltered, commercially available triamcinolone acetonide intravitreally, before silicone oil injection. The patients were followed for a mean of 4.7 months (range 1-15 months), and demographic as well as pertinent preoperative and postoperative clinical information was gathered. Results: At the last follow-up visit, vision had improved in 4 eyes, remained stable in 5 eyes, and worsened in 4 eyes. The retina was attached at the end of follow-up in 10 of the 13 eyes. Eight of the 13 eyes did not show any clinical signs of reproliferation or redetachment during the course of follow-up. The mean intraocular pressure did not increase (preoperative value was 10.8 6.22 mm Hg with a range of 0-22 mm Hg; at last follow-up, mean pressure was 9.6 +/- 3.86 mm Hg with a cumulative postoperative range of 0-26 mm Hg). Steroid crystals were visible at 1 month postoperatively in 3 eyes and did not hinder fundus examination significantly. Interpretation: The intravitreal injection of low-dose, unaltered triamcinolone acetonide in the setting of pars plana vitrectomy and silicone oil injection for the treatment of proliferative vitreoretinopathy and complicated proliferative diabetic retinopathy appears to be well tolerated. Further controlled study is needed to clearly define the potential beneficial effects of intravitreal steroids in these 2 disease processes.
引用
收藏
页码:598 / 604
页数:7
相关论文
共 50 条
  • [1] CYTOKINES IN PROLIFERATIVE DIABETIC-RETINOPATHY AND PROLIFERATIVE VITREORETINOPATHY
    ELNER, SG
    ELNER, VM
    JAFFE, GJ
    STUART, A
    KUNKEL, SL
    STRIETER, RM
    CURRENT EYE RESEARCH, 1995, 14 (11) : 1045 - 1053
  • [2] Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy
    Abu El-Asrar, Ahmed M.
    Struyf, Sofie
    Kangave, Dustan
    Geboes, Karel
    Van Damme, Jo
    EUROPEAN CYTOKINE NETWORK, 2006, 17 (03) : 155 - 165
  • [3] Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy
    Liting Hu
    Qiulu Chen
    Zhaodong Du
    Wenying Wang
    Guiqiu Zhao
    International Ophthalmology, 2021, 41 : 1635 - 1642
  • [4] Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy
    Hu, Liting
    Chen, Qiulu
    Du, Zhaodong
    Wang, Wenying
    Zhao, Guiqiu
    INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (05) : 1635 - 1642
  • [5] Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema
    Kaderli B.
    Avci R.
    Gelisken O.
    Yucel A.Â.
    International Ophthalmology, 2005, 26 (6) : 207 - 214
  • [6] Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage
    Spaide, Richard F.
    Fisher, Yale L.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03): : 275 - 278
  • [7] MIDTERM RESULTS OF LOW-DOSE INTRAVITREAL TRIAMCINOLONE AS ADJUNCTIVE TREATMENT FOR PROLIFERATIVE VITREORETINOPATHY
    Chen, Weiqi
    Chen, Haoyu
    Hou, Ping
    Fok, Andrew
    Hu, Yijun
    Lam, Dennis S. C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (06): : 1137 - 1142
  • [8] Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy
    Barile, GR
    Chang, S
    Park, L
    Reppucci, VS
    Schiff, WM
    Schmidt, AM
    CURRENT EYE RESEARCH, 1999, 19 (03) : 219 - 227
  • [9] C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy
    Capeans, C
    De Rojas, MV
    Lojo, S
    Salorio, MS
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 1998, 18 (06): : 546 - 550
  • [10] Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy
    Benhmidoune, L.
    Mchachi, A.
    Boukhrissa, M.
    Chakib, A.
    Rachid, R.
    Elbelhadji, M.
    Amraoui, A.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2013, 36 (09): : 758 - 763